I was delighted to be able to reach out to all of you earlier today to reveal to you the paradigm shift that we have achieved through Zygotron‘s innovative out-of-the-box thinking modalities.

The outstandingly positive results of our pivotal trial speak to our glowing destiny. I trust your discretion. Although the headline values may be reported, we must keep the details confidential for now, until rubber-stamped by the journal with which we have formed an arrangement, or at least until recruitment is complete.

To better position the company to compete in a fragmented and competitive market, Zygotron will transition from the launch thoughtspace that spanned the full panorama of cellular biotherapeutics, to the more focused business environment of cardiac dysfunction in heart failure and myocardial infarction. Manufacturing of our key blastosome nucelobionics technology will fluidly move to the new phytometabolic platform during the next FY, with key deliverables being hit at end of play.

We are committed to working towards right-sized standards of scientific and business ethics, and in alignment with this we have continued our ongoing transformation program.

Congress Session “The Emerging Role of Metadynamics” – arranged by our consultants

We have secured the major thought leaders in heart failure in all 3 continents through our program of re-purposing of scientific congresses with global reach, and they have confirmed their brand alignment to Zygotron which is already reaping dividends. We have gone offline and widened our footprint arising through funding issues in Continuing Medical Education systems to transition vanilla education programs into consciousness-raising themed sessions that are market-generative.

Through our influential contacts we have obtained a highly competitive place in the family of sessions entitled “The Emerging Role Of …” which focus on therapies whose validity is obvious to the far-sighted visionaries of the financial world long before it becomes apparent through conventional pre-paradigm-shift research processes.

Our legal department has hit the ground running with all hands on deck, interfacing with the major cardiovascular journals to underline their fiduciary responsibility to Zygotron as paying customers, and the mutually undesirable consequences of any remarks that are not win-win.

We have bandwidthed the resonance of our internal knowledge economy, keeping our scientific knowhow segregated into silos so that no individual human capital element could externalize our technology to a competitor. While this introduces some challenges our Chief Medical Officer makes face-time to touch base with our statistical and marketing leads to ensure the idea flow is not vulnerable to flight risk.

We are in a stronger position today than ever before.

Charles Dawson BA, MBA
CEO Zygotron Metadynamics